Richie Jain
About Richie Jain
Richie Jain is Executive Vice President, Chief Financial Officer (Principal Financial Officer) of Schrödinger, Inc., appointed May 16, 2025 at age 41 . He previously led Strategic Finance and Corporate/Business Development at Schrödinger (Feb 2024–May 2025), and before that was a Managing Director in healthcare investment banking and M&A at Morgan Stanley (2020–2023; joined Morgan Stanley in 2010). He began his career as an electrical engineer in Boston Scientific’s cardiac rhythm management business. He holds a B.S. in electrical engineering (University of Michigan) and an M.B.A. (University of Chicago Booth) . Since appointment, he has signed SOX 302 and 906 certifications on company 10-Qs (Q2 and Q3 2025), indicating responsibility for disclosure controls and fair presentation of financials .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Schrödinger, Inc. | SVP, Strategic Finance; Head of Corporate & Business Development | Feb 2024–May 2025 | Led corporate/business development, venture & equity investments, strategic planning and valuation |
| Morgan Stanley & Co. LLC | Managing Director, Healthcare IB & M&A; roles of increasing responsibility | 2010–2023 (MD: 2020–2023) | Executed healthcare investment banking and M&A mandates |
| Boston Scientific | Electrical Engineer, Cardiac Rhythm Management | N/D | Technical engineering in CRM product area |
External Roles
| Organization | Role | Years | Notes |
|---|---|---|---|
| — | — | — | No public-company board roles disclosed; no related-party transactions under Item 404(a) |
Fixed Compensation
| Year | Base Salary ($) | Target Bonus (%) | Notes |
|---|---|---|---|
| 2025 | 535,000 | 55% of annualized base (prorated from May 16–Dec 31, 2025); plus prorated bonus Jan 1–May 16 for prior role | Employment Agreement effective May 16, 2025 |
Performance Compensation
| Incentive Type | Metric | Weighting | Target | Actual | Payout Mechanics | Vesting |
|---|---|---|---|---|---|---|
| Annual Cash Incentive | Company quantitative and qualitative goals (Comp Committee) | Not disclosed | 55% of base (prorated 2025) | Not disclosed | Paid under Senior Executive Incentive Compensation Plan | N/A (cash) |
| RSUs | Service-based | N/A | 9,375 units expected grant | N/A | Vests in equal annual installments over four years | First vest approx. May 16, 2026; annually thereafter |
| Stock Options | Service-based | N/A | 18,750 options expected grant | N/A | Exercise price at grant-date close; time-based vesting | 25% at 1-year anniversary; remainder monthly through year 4 |
Compensation program design emphasizes “at risk” pay tied to performance and long-term equity; Comp Committee targets around the 50th percentile vs peer group, with individual outcomes based on performance, role criticality, and internal equity .
Equity Ownership & Alignment
| Category | Detail |
|---|---|
| Beneficial Ownership (initial Form 3) | 27,722 common shares direct; includes 26,155 unvested RSUs (composition partially itemized in filing) |
| Options Outstanding | 35,000 options, $26.04 strike, exp. 03/15/2034 |
| Options Outstanding | 15,990 options, $21.24 strike, exp. 03/03/2035 |
| 2025 Expected Grants at Appointment | 18,750 options at grant-date close, time-based vesting (25% at 1-year, then monthly), 9,375 RSUs vesting annually over four years |
| Pledging/Hedging | No pledging indicated in Form 3; no hedging disclosure noted in appointment filing |
| Ownership Guidelines | Not disclosed for Jain individually in filings cited |
Employment Terms
- At-will employment as EVP & CFO, based in New York, NY and New Jersey; reports to CEO; full-time duties with permitted outside activities that are non-competitive and non-conflicting .
- Indemnification agreement per standard company form (referenced to S-1 exhibit) .
- Eligible to participate in the Amended and Restated Executive Severance and Change in Control Benefits Plan; severance contingent on release and compliance with restrictive covenants; specific multiples for Jain not enumerated in the 8-K .
- Confidentiality, inventions, non-competition, and non-solicitation agreement executed with employment .
- Compensation subject to annual review by the Board/Compensation Committee .
Investment Implications
- Alignment: Initial holdings (27,722 shares including substantial unvested RSUs) and multi-year vesting of options/RSUs align incentives with long-term equity value; no pledging disclosed, reducing alignment risk .
- Retention: Four-year vest schedules with first option/RSU vest around May 16, 2026 create retention hooks; participation in severance/CoC plan provides downside protection but details for Jain’s multiples are not in the 8-K .
- Trading signals: No Form 4 transactions surfaced in filings reviewed through November 5, 2025; expect Form 4 activity around annual RSU vests and monthly option vesting post first anniversary, which may indicate liquidity needs or confidence .
- Execution risk: CFO certifications (SOX 302/906) in Q2 and Q3 2025 underscore accountability for controls and reporting quality during transition from prior CFO; background in healthcare IB/M&A plus internal strategic finance experience may support capital allocation and BD execution .